**Appendix Table E30. Study design characteristics of studies assessing the predictive ability of VerifyNow in patients with cerebrovascular disease**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author**  **Year**  **PMID**  **Country**  **Study Name** | **Study design** | **Multicenter (yes/no)** | **Recruitment method** | **Sampling population** | **Enroment period** | **Mean or median (state which follow up duration)** | **Setting** | **A Priori power analysis performed? (if yes, was accrual 80% of target or higher)** | **Funding** |
| Ryu, 2010{Ryu, 2010 229 /id}  21113358  South Korea  NR | Prospective | NO | NR | Patients receiving a neurointervention | Jan. 2007 to July 2008 | 18.2 ± 7.84 months mean/SD | In hospital at baseline, outpatient followup at 6 mo | NR | Non-industry only |
| Drazin, 2011{Drazin, 2011 238 /id}  21990814  US  NR | Prospective | NR | Consecutive | Patients undergoing neurovascular stenting and receiving clopidogrel and aspirin | 2007-2009 | Mean 12 mo (range, 0-34 mo) | Intraoperative + in- and outpatient followup | NO | NR but one author has consulting fees, and one has grants, from industry |
| Kang, 2010{Kang, 2010 1 /id}  20223886  South Korea  NR | observational study | NO | NR | patients undergoing coil embolization for intracranial aneurysms | Since Mar 2008 | Max 60 days | followup after intervention | NO | NR |
|  |  |  |  |  |  |  |  |  |  |

ACS = acute coronary syndrome; AMI = acute myocardial infarction; CAD = coronary artery disease; MI = myocardial infarction; NSTE = non-ST-elevation; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI = ST-elevation MI; DES=drug eluting stent; CABG=coronary artery bypass grafting; AA= arachidonic acid; SD=standard deviation; RCT=randomized controlled trial; NR=not reported;